The Short Form-36: Pre- Versus Post-Surgical Administration in Cardiac Surgery Patients

Weill Medical College of Cornell University50 enrolled

Overview

The purpose of this study is to determine whether the SF-36 can be administered reliably to cardiac surgery patients (two to three days) post-surgery, with the patient answering the questions of this survey from a pre-surgical perspective.

The purpose of this study, is to determine whether the SF-36 can be administered reliably to cardiac surgery patients (two to three days) post-surgery, with the patient answering the questions of this survey from a pre-surgical perspective.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Coronary Artery Bypass Grafting Heart Diseases Heart Valve Diseases

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Cardiac surgery patients who are between the ages of 18 and 100 * Are English speaking * Able to give consent * Undergoing cardiac surgery including (but not limited to): * Aortic valve replacement (AVR) * Mitral valve replacement (MVR) * Tricuspid valve replacement (TVR) * Coronary artery bypass graft (CABG). Exclusion Criteria: * Non-cardiac surgery patients

Locations (1)

The New York Presbyterian Hospital-Weill Medical Center

New York, New York, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.